GLUE
NASDAQ · Biotechnology
Monte Rosa Therapeutics Inc
$10.57
+0.00 (+0.00%)
Financial Highlights (FY 2026)
Revenue
130.97M
Net Income
-40,909,231
Gross Margin
—
Profit Margin
-31.2%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 53.0% | 53.0% | 53.0% |
| Operating Margin | -43.8% | -10.3% | -9.8% | -9.1% |
| Profit Margin | -31.2% | -7.3% | -8.6% | -8.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 130.97M | 401.98M | 400.93M | 375.33M |
| Gross Profit | — | 213.23M | 212.67M | 199.09M |
| Operating Income | -57,404,643 | -41,589,522 | -39,291,866 | -34,163,729 |
| Net Income | -40,909,231 | -29,192,444 | -34,329,564 | -33,264,511 |
| Gross Margin | — | 53.0% | 53.0% | 53.0% |
| Operating Margin | -43.8% | -10.3% | -9.8% | -9.1% |
| Profit Margin | -31.2% | -7.3% | -8.6% | -8.9% |
| Rev Growth | — | +22.8% | -9.2% | -6.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 539.88M | 596.36M | 525.46M |
| Total Equity | — | 1.24B | 1.24B | 1.15B |
| D/E Ratio | — | 0.43 | 0.48 | 0.46 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -48,563,216 | -51,685,540 | -47,809,490 | -46,631,390 |
| Free Cash Flow | — | -50,874,519 | -44,333,819 | -47,871,864 |